about
An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodiesCKD and Its Risk Factors among Patients with Cystinuria.Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter studyGenome-Wide Association Study of Acute Renal Graft Rejection.Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches.Uterus transplantation in France: for which patients?Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation.Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study.Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation.HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms.eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode.Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist.Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients.Recurrence of renal cell cancer after renal transplantation in a multicenter French cohort.Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.Severe renal impairment during triple therapy with telaprevir.Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.[Uterine transplantation: is there a real demand?].Uterus human leucocyte antigen expression in the perspective of transplantation.Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphismsRenal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevirHow to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigationThe COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?
P50
Q33865743-A276A531-E91F-4997-AE29-EF9FD4DF0000Q35576095-715917BD-F686-4ED5-B07F-1FBBF58F374CQ35834706-753ACD9C-5B35-4A30-B935-2A8BF2852189Q37560649-655031E3-73CA-4052-A8B4-5319AC505E11Q38893247-A862A68D-9729-4A0B-92B4-C2D743969E31Q38914846-616D22D0-D6A9-49D1-AFA1-54726458271BQ39463143-27BBC8DE-D69A-4CE5-9F24-F1C316D2F686Q39743523-D1E5E541-E41C-44D0-8967-1246F4795042Q39984421-01FE22F1-A96A-4014-A88A-CB4E1D9FEAB1Q40169677-737C5374-6EF5-419C-96A9-D8F06040103CQ40320279-1CD145DF-19A2-4BD3-95B5-C83BD9ADB9F3Q40806698-567C39BF-5EA3-4B95-ACEF-14BE296F8F31Q40922185-C8DBAE28-6882-437C-A023-19904D88C715Q41001229-758692D3-F866-4D2F-AD42-7A0AABCFB6C0Q41471865-83966498-3AB0-4D50-89EA-001DB68E449EQ42205243-EA80E583-5555-4DEA-A46C-6C7A07E6706FQ43515296-3EAD3717-EF3E-4A76-B235-6C9EF72C2540Q44270926-E7A28635-871C-4160-BF49-2C086F5D8171Q44738359-F4EC12D2-B258-4C68-A5AD-9BA9DCFAD499Q47352044-B1042FD0-D159-47FC-9CE1-52A70DAE6858Q50152116-84317FB4-4623-4B7B-9304-DF9C7495C76DQ50545773-C9CFED3D-44DC-4E46-9881-8701F1673281Q53551249-B4CD69FE-97D2-4437-8E9C-CCA629DFD79CQ53642133-2F9EF3F6-C018-443B-841F-25A856E23C48Q53745794-4670B29F-5F09-411D-AEB2-47F79E888DD3Q56878901-E1F55ECC-29EB-4138-AB10-005D60B56379Q85198864-458EE7EA-8844-41F4-B049-D53225638958Q86023400-CB16AD43-E567-4240-A534-729AC63F596FQ94484146-9B7598DD-4AAE-407F-BC7D-A3120BBE31D3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Essig
@ast
M Essig
@en
M Essig
@es
M Essig
@nl
M Essig
@sl
type
label
M Essig
@ast
M Essig
@en
M Essig
@es
M Essig
@nl
M Essig
@sl
prefLabel
M Essig
@ast
M Essig
@en
M Essig
@es
M Essig
@nl
M Essig
@sl
P106
P108
P31
P496
0000-0002-2030-5616